Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 13 | 6 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 9 | 4 | 0 | 0 |
| 2M Ago | 3 | 3 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $182.8, a high estimate of $235.00, and a low estimate of $128.00. Marking an increase of 10.38%, the current average surpasses the previous average price target of $165.61.
Decoding Analyst Ratings: A Detailed Look
The standing of Sarepta Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Biren Amin | Piper Sandler | Maintains | Overweight | $205.00 | $205.00 |
| Gil Blum | Needham | Maintains | Buy | $235.00 | $235.00 |
| David Hoang | Citigroup | Raises | Neutral | $176.00 | $172.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $200.00 | $165.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Raises | In-Line | $185.00 | $139.00 |
| Kostas Biliouris | BMO Capital | Raises | Outperform | $200.00 | $170.00 |
| Mani Foroohar | Leerink Partners | Raises | Outperform | $230.00 | $165.00 |
| Matthew Harrison | Morgan Stanley | Maintains | Overweight | $165.00 | $165.00 |
| Biren Amin | Piper Sandler | Maintains | Overweight | $157.00 | $157.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | $128.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $182.00 | $142.00 |
| Gena Wang | Barclays | Raises | Overweight | $226.00 | $185.00 |
| Brian Skorney | Baird | Raises | Outperform | $200.00 | $170.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $213.00 | $166.00 |
| Gil Blum | Needham | Raises | Buy | $235.00 | $166.00 |
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $170.00 | $170.00 |
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $170.00 | $170.00 |
| Biren Amin | Piper Sandler | Announces | Overweight | $157.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $142.00 | $157.00 |
| Gil Blum | Needham | Maintains | Buy | $166.00 | $166.00 |
| Uy Ear | Mizuho | Raises | Buy | $179.00 | $145.00 |
| Hartaj Singh | Oppenheimer | Announces | Outperform | $180.00 | - |
| Anupam Rama | JP Morgan | Lowers | Overweight | $175.00 | $177.00 |
| Gil Blum | Needham | Maintains | Buy | $166.00 | $166.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | $128.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sarepta Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sarepta Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Sarepta Therapeutics: A Financial Overview
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 63.1%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.97%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.11%, the company showcases effective utilization of assets.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 1.44, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.